Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
NCT02049151 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
- Lead sponsor
- EMD Serono
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- March 31, 2014
- Completion date
- July 31, 2015
- Enrollment
- 35 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.